These results suggest that metronomic Celecoxib treatment inhibited the invasive behavior of HCC cells through the suppression of NFκB transcriptional activity, and the mechanisms involved were independent of the COX-2/PGE2 pathway. The gene discussed is NFKB1; the disease is hepatocellular carcinoma.